500 ARSENAL STREET, WATERTOWN, MA
News, Underwriting Agreement, Legal Opinion
Investor Presentation
Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Changes in Board, Management or Compensation
Files Patent Infringement Suit Against in the Unified Patent Court of the European Union
Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
Earnings Release
News, Material Contracts
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence